Comprehensive molecular profiling of lung adenocarcinoma
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Adenocarcinoma of the lung is the leading cause of cancer death worldwide. Here we report molecular profiling of 230 resected lung adenocarcinomas using messenger RNA, microRNA and DNA sequencing integrated with copy number, methylation and proteomic analyses. High rates of somatic mutation were seen (mean 8.9 mutations per megabase). Eighteen genes were statistically significantly mutated, including RIT1 activating mutations and newly described loss-of-function MGA mutations which are mutually exclusive with focal MYC amplification. EGFR mutations were more frequent in female patients, whereas mutations in RBM10 were more common in males. Aberrations in NF1, MET, ERBB2 and RIT1 occurred in 13% of cases and were enriched in samples otherwise lacking an activated oncogene, suggesting a driver role for these events in certain tumours. DNA and mRNA sequence from the same tumour highlighted splicing alterations driven by somatic genomic changes, including exon 14 skipping in MET mRNA in 4% of cases. MAPK and PI(3)K pathway activity, when measured at the protein level, was explained by known mutations in only a fraction of cases, suggesting additional, unexplained mechanisms of pathway activation. These data establish a foundation for classification and further investigations of lung adenocarcinoma molecular pathogenesis. An integrated transcriptome, genome, methylome and proteome analysis of over 200 lung adenocarcinomas reveals high rates of somatic mutations, 18 statistically significantly mutated genes including RIT1 and MGA, splicing changes, and alterations in MAPK and PI(3)K pathway activity. This report from The Cancer Genome Atlas Research Network presents molecular profiling of 230 resected untreated lung adenocarcinomas. Integrated analyses of transcriptome, genome, methylome and proteome collectively identify high rates of somatic mutation, significantly mutated genes including RIT1 and MGA, splicing alterations driven by somatic genomic changes, and point to as yet unidentified lesions that alter MAPK and PI(3)K pathway activity. These data establish a foundation for classification and further investigations of the leading cause of cancer death worldwide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Landmark large scale sequencing studies have established a census of major KRAS co-mutations in both early-stage and advanced LUAD15, 34, 59, 62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutations in PIK3CA and CTNNB1 are more frequent in advanced stage tumors compared with early stage LUADs, pointing towards functional roles in malignant progression and metastasis, whereas alterations in TP53 (62.5%), RB1 (9.5 −12.5%) and NKX2–1 (12.5%) appear to occur with comparable frequencies in early- and advanced-stage tumors15, 34, 72, 73.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“earlier studies that identified a central role for WNT signaling in LUAD metastasis”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inactivating mutations or loss of STK11/LKB1, which define one of the major genomic sub-groups of KRAS-mutant lung cancers1,19,62, are of particular interest because they are associated with decreased responsiveness to immune checkpoint blockade9,63 and poor overall prognosis64.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Importantly, large-scale profiling studies utilizing either whole exome sequencing or broad targeted sequencing panels in NSCLC tumors have revealed multiple non-random patterns of co-occurring or mutually exclusive mutations, which typically vary depending on the particular oncogenic driver mutation15, 34, 58–62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationMutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationSensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981
Travis, W. D., Brambilla, E., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell, C. A., Riely, G. J., Van Schil, P. E., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318206a221 · Cited by 4,792
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446 · cited 1×
“Analysis of mutations in PIK3CA and STK11, STK11 protein levels, and AMPK and AKT phosphorylation(33) led to the identification of three major mTOR patterns in lung adenocarcinoma: (1) tumours with minimal or basal mTOR pathway activation, (2) tumours showing higher mTOR activity accompanied by either STK11-inactivati…”
BackgroundComprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Self-citationBhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191502998 · Cited by 2,576
Massive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414
Cited by
Items 401–500 of 1,045
Molecular Mechanisms of Pulmonary Fibrogenesis and Its Progression to Lung Cancer: A Review
Kinoshita, T., & Goto, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061461 · Cited by 176
An Immune-Related Signature Predicts Survival in Patients With Lung Adenocarcinoma
Zhang, M., Zhu, K., Pu, H., Wang, Z., Zhao, H., Zhang, J., & Wang, Y. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01314 · Cited by 177
Ooki, A., Maleki, Z., Tsay, J.-C. J., Goparaju, C., Brait, M., Turaga, N., Nam, H.-S., Rom, W. N., Pass, H. I., Sidransky, D., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1222 · Cited by 175
Nahar, R., Zhai, W., Zhang, T., Takano, A., Khng, A. J., Lee, Y. Y., Liu, X., Lim, C. H., Koh, T. P. T., Aung, Z. W., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02584-z · Cited by 173
The potential of siRNA based drug delivery in respiratory disorders: Recent advances and progress
Dua, K., Wadhwa, R., Singhvi, G., Rapalli, V., Shukla, S. D., Shastri, M. D., Gupta, G., Satija, S., Mehta, M., Khurana, N., et al. (2019) · Drug Development Research · doi:10.1002/ddr.21571 · Cited by 175
Precision therapy for RET-altered cancers with RET inhibitors
Thein, K. Z., Velcheti, V., Mooers, B. H. M., Wu, J., & Subbiah, V. (2021) · Trends in Cancer · doi:10.1016/j.trecan.2021.07.003 · Cited by 169
An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer
Xue, Y., Martelotto, L., Baslan, T., Vides, A., Solomon, M., Mai, T. T., Chaudhary, N., Riely, G. J., Li, B. T., Scott, K., et al. (2017) · Nature Medicine · doi:10.1038/nm.4369 · Cited by 174
“BRAF mutations are found in approximately 7% of cancer patients, particularly those with melanoma, colorectal, thyroid or lung cancer 1,2 .”
The role of neoantigens in response to immune checkpoint blockade
Riaz, N., Morris, L., Havel, J. J., Makarov, V., Desrichard, A., & Chan, T. A. (2016) · International Immunology · doi:10.1093/intimm/dxw019 · Cited by 175
Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinoma
Song, Q., Shang, J., Yang, Z., Zhang, L., Zhang, C., Chen, J., & Wu, X. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1824-4 · Cited by 174
“Adenocarcinoma (LUAD) and squamous cell carcinoma are two main types of NSCLC [3], of which LUAD is the most common type [4].”
Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma
Hu, X., Fujimoto, J., Ying, L., Fukuoka, J., Ashizawa, K., Sun, W., Reuben, A., Chow, C.-W., McGranahan, N., Chen, R., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10877-8 · Cited by 173
Lung Adenocarcinoma Tumor Origin: A Guide for Personalized Medicine
Seguin, L., Durandy, M., & Feral, C. C. (2022) · Cancers · doi:10.3390/cancers14071759 · Cited by 171
Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping
Heist, R. S., Sequist, L. V., Borger, D., Gainor, J. F., Arellano, R. S., Le, L. P., Dias-Santagata, D., Clark, J. W., Engelman, J. A., Shaw, A. T., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.06.013 · Cited by 169
Reungwetwattana, T., Liang, Y., Zhu, V., & Ou, S.-H. I. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2016.11.011 · Cited by 169
Schrock, A. B., Li, S. D., Frampton, G. M., Suh, J., Braun, E., Mehra, R., Buck, S. C., Bufill, J. A., Peled, N., Karim, N. A., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.03.005 · Cited by 173
Detecting repeated cancer evolution from multi-region tumor sequencing data
Caravagna, G., Giarratano, Y., Ramazzotti, D., Tomlinson, I., Graham, T. A., Sanguinetti, G., & Sottoriva, A. (2018) · Nature Methods · doi:10.1038/s41592-018-0108-x · Cited by 173
Mack, P. C., Banks, K. C., Espenschied, C. R., Burich, R. A., Zill, O. A., Lee, C. E., Riess, J. W., Mortimer, S. A., Talasaz, A., Lanman, R. B., et al. (2020) · Cancer · doi:10.1002/cncr.32876 · Cited by 172
Brain metastasis: Unique challenges and open opportunities
Lowery, F. J., & Yu, D. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.12.001 · Cited by 170
Dost, A. F. M., Moye, A. L., Vedaie, M., Tran, L. M., Fung, E., Heinze, D., Villacorta-Martin, C., Huang, J., Hekman, R., Kwan, J. H., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.07.022 · Cited by 170
“…1–16, October 1, 2020 ª 2020 Elsevier Inc. 1 ll Please cite this article in press as: Dost et al., Organoids Model Transcriptional Hallmarks of Oncogenic KRAS Activation in Lung Epithelial Progenitor Cells, Cell Stem Cell (2020), https://doi.org/10.1016/j.stem.2020.07.022 (Collisson et al., 2014).”
BackgroundInfluentialMCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents
Bolomsky, A., Vogler, M., Köse, M. C., Heckman, C. A., Ehx, G., Ludwig, H., & Caers, J. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01007-9 · Cited by 168
Niu, Z., Jin, R., Zhang, Y., & Li, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01200-x · Cited by 170
Owada-Ozaki, Y., Muto, S., Takagi, H., Inoue, T., Watanabe, Y., Fukuhara, M., Yamaura, T., Okabe, N., Matsumura, Y., Hasegawa, T., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.003 · Cited by 170
Kwak, E. L., Ahronian, L. G., Siravegna, G., Mussolin, B., Borger, D. R., Godfrey, J. T., Jessop, N. A., Clark, J. W., Blaszkowsky, L. S., Ryan, D. P., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0748 · Cited by 169
Activating MET kinase rearrangements in melanoma and Spitz tumours
Yeh, I., Botton, T., Talevich, E., Shain, A. H., Sparatta, A. J., de la Fouchardiere, A., Mully, T. W., North, J. P., Garrido, M. C., Gagnon, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms8174 · Cited by 167
EGFR TKI combination with immunotherapy in non-small cell lung cancer
Ahn, M.-J., Sun, J.-M., Lee, S.-H., Ahn, J. S., & Park, K. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1300656 · Cited by 169
Non-canonical functions of the RB protein in cancer
Dick, F. A., Goodrich, D. W., Sage, J., & Dyson, N. J. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0008-5 · Cited by 168
Wang, K., Ji, W., Yu, Y., Li, Z., Niu, X., Xia, W., & Lu, S. (2018) · Oncogene · doi:10.1038/s41388-018-0311-3 · Cited by 169
Immune Escape Mechanisms in Non Small Cell Lung Cancer
Anichini, A., Perotti, V. E., Sgambelluri, F., & Mortarini, R. (2020) · Cancers · doi:10.3390/cancers12123605 · Cited by 169
Crizotinib in Patients With MET-Amplified NSCLC
Camidge, D. R., Otterson, G. A., Clark, J. W., Ignatius Ou, S.-H., Weiss, J., Ades, S., Shapiro, G. I., Socinski, M. A., Murphy, D. A., Conte, U., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.02.010 · Cited by 166
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall
Leonetti, A., Facchinetti, F., Rossi, G., Minari, R., Conti, A., Friboulet, L., Tiseo, M., & Planchard, D. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.006 · Cited by 168
NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes
Singh, A., Daemen, A., Nickles, D., Jeon, S.-M., Foreman, O., Sudini, K., Gnad, F., Lajoie, S., Gour, N., Mitzner, W., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1985 · Cited by 167
Zhou, X., Wen, W., Shan, X., Zhu, W., Xu, J., Guo, R., Cheng, W., Wang, F., Qi, L.-W., Chen, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14311 · Cited by 166
Frank, R., Scheffler, M., Merkelbach-Bruse, S., Ihle, M. A., Kron, A., Rauer, M., Ueckeroth, F., König, K., Michels, S., Fischer, R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3416 · Cited by 167
Large-scale profiling of microRNAs for The Cancer Genome Atlas
Chu, A., Robertson, G., Brooks, D., Mungall, A. J., Birol, I., Coope, R., Ma, Y., Jones, S., & Marra, M. A. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv808 · Cited by 165
Hirano, T., Yasuda, H., Tani, T., Hamamoto, J., Oashi, A., Ishioka, K., Arai, D., Nukaga, S., Miyawaki, M., Kawada, I., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5887 · Cited by 165
Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations
Pahuja, K. B., Nguyen, T. T., Jaiswal, B. S., Prabhash, K., Thaker, T. M., Senger, K., Chaudhuri, S., Kljavin, N. M., Antony, A., Phalke, S., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.09.010 · Cited by 164
Binkley, M. S., Jeon, Y.-J., Nesselbush, M., Moding, E. J., Nabet, B. Y., Almanza, D., Kunder, C., Stehr, H., Yoo, C. H., Rhee, S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0282 · Cited by 163
KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer
Krall, E. B., Wang, B., Munoz, D. M., Ilic, N., Raghavan, S., Niederst, M. J., Yu, K., Ruddy, D. A., Aguirre, A. J., Kim, J. W., et al. (2017) · eLife · doi:10.7554/elife.18970 · Cited by 160
Vansteenkiste, J. F., Canon, J.-L., De Braud, F., Grossi, F., De Pas, T., Gray, J. E., Su, W.-C., Felip, E., Yoshioka, H., Gridelli, C., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000607 · Cited by 162
Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease
Hiley, C. T., Le Quesne, J., Santis, G., Sharpe, R., de Castro, D. G., Middleton, G., & Swanton, C. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31340-x · Cited by 163
MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale
Salgia, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0472 · Cited by 163
Kitai, H., Ebi, H., Tomida, S., Floros, K. V., Kotani, H., Adachi, Y., Oizumi, S., Nishimura, M., Faber, A. C., & Yano, S. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1377 · Cited by 162
Ong, P. S., Wang, L. Z., Dai, X., Tseng, S. H., Loo, S. J., & Sethi, G. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00395 · Cited by 162
Danilova, L., Wang, H., Sunshine, J., Kaunitz, G. J., Cottrell, T. R., Xu, H., Esandrio, J., Anders, R. A., Cope, L., Pardoll, D. M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607836113 · Cited by 161
LeBoeuf, S. E., Wu, W. L., Karakousi, T. R., Karadal, B., Jackson, S. R., Davidson, S. M., Wong, K.-K., Koralov, S. B., Sayin, V. I., & Papagiannakopoulos, T. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.012 · Cited by 150
Inactivation of Capicua drives cancer metastasis
Okimoto, R. A., Breitenbuecher, F., Olivas, V. R., Wu, W., Gini, B., Hofree, M., Asthana, S., Hrustanovic, G., Flanagan, J., Tulpule, A., et al. (2017) · Nature Genetics · doi:10.1038/ng.3728 · Cited by 160
The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma
Caso, R., Sanchez-Vega, F., Tan, K. S., Mastrogiacomo, B., Zhou, J., Jones, G. D., Nguyen, B., Schultz, N., Connolly, J. G., Brandt, W. S., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.08.005 · Cited by 160
Faruki, H., Mayhew, G. M., Serody, J. S., Hayes, D. N., Perou, C. M., & Lai-Goldman, M. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.03.010 · Cited by 159
“Serine/ threonine kinase 11 gene (STK11) deletion, high proliferation, brain metastases, and poor prognosis characterize the PP subtype, and tumor protein p53 gene (TP53) mutations are more characteristic of the PI subtype.(2,4,5) The SCC subtypes are enriched for retinoblastoma 1 gene (RB1) loss in the primitive subt…”
BackgroundMolecular biomarkers for lung adenocarcinoma
Calvayrac, O., Pradines, A., Pons, E., Mazières, J., & Guibert, N. (2017) · European Respiratory Journal · doi:10.1183/13993003.01734-2016 · Cited by 158
Miret, J. J., Kirschmeier, P. T., Koyama, S., Zhu, M., Li, Y. Y., Naito, Y., Wu, M., Malladi, V. S., Huang, W., Walker, W., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0504-5 · Cited by 170
Drugging KRAS: Current perspectives and state-of-art review
Parikh, K., Banna, G., Liu, S. V., Friedlaender, A., Desai, A., Subbiah, V., & Addeo, A. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01375-4 · Cited by 164
Systematic identification of genes with a cancer-testis expression pattern in 19 cancer types
Wang, C., Gu, Y., Zhang, K., Xie, K., Zhu, M., Dai, N., Jiang, Y., Guo, X., Liu, M., Dai, J., et al. (2016) · Nature Communications · doi:10.1038/ncomms10499 · Cited by 158
Yu, K., Chen, B., Aran, D., Charalel, J., Yau, C., Wolf, D. M., van ‘t Veer, L. J., Butte, A. J., Goldstein, T., & Sirota, M. (2019) · Nature Communications · doi:10.1038/s41467-019-11415-2 · Cited by 156
CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers
Kong, T., Ahn, R., Yang, K., Zhu, X., Fu, Z., Morin, G., Bramley, R., Cliffe, N. C., Xue, Y., Kuasne, H., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1108 · Cited by 175
Fernando, T. M., Piskol, R., Bainer, R. O., Sokol, E. S., Trabucco, S. E., Zhang, Q., Trinh, H., Maund, S. L., Kschonsak, M., Chaudhuri, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19402-8 · Cited by 180
Tracking Cancer Evolution through the Disease Course
Bailey, C., Black, J. R. M., Reading, J. L., Litchfield, K., Turajlic, S., McGranahan, N., Jamal-Hanjani, M., & Swanton, C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1559 · Cited by 158
NRF2 activation induces NADH-reductive stress, providing a metabolic vulnerability in lung cancer
Weiss‐Sadan, T., Ge, M., Hayashi, M., Gohar, M., Yao, C.-H., de Groot, A., Harry, S. A., Carlin, A. D., Fischer, H., Shi, L., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.01.012 · Cited by 172
Shea, M., Costa, D. B., & Rangachari, D. (2015) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465815617871 · Cited by 166
Cha, Y. J., Kim, H. R., Lee, C. Y., Cho, B. C., & Shim, H. S. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.05.001 · Cited by 157
Subtype-GAN: a deep learning approach for integrative cancer subtyping of multi-omics data
Yang, H., Chen, R., Li, D., & Wang, Z. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btab109 · Cited by 156
Gal, K. L., Schmidt, E. E., & Sayin, V. I. (2021) · Antioxidants · doi:10.3390/antiox10091377 · Cited by 184
Dhanasekaran, S. M., Alejandro Balbin, O., Chen, G., Nadal, E., Kalyana-Sundaram, S., Pan, J., Veeneman, B., Cao, X., Malik, R., Vats, P., et al. (2014) · Nature Communications · doi:10.1038/ncomms6893 · Cited by 155
Chuang, C.-H., Greenside, P. G., Rogers, Z. N., Brady, J. J., Yang, D., Ma, R. K., Caswell, D. R., Chiou, S.-H., Winters, A. F., Grüner, B. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4285 · Cited by 156
Update on Immunohistochemistry for the Diagnosis of Lung Cancer
Inamura, K. (2018) · Cancers · doi:10.3390/cancers10030072 · Cited by 183
Carrot‐Zhang, J., Soca‐Chafre, G., Patterson, N. J., Thorner, A. R., Nag, A., Watson, J., Genovese, G., Rodríguez, J. K., Gelbard, M. K., Corrales, L., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1165 · Cited by 164
The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation
Martin, T. D., Patel, R. S., Cook, D. R., Choi, M. Y., Patil, A., Liang, A. C., Li, M. Z., Haigis, K. M., & Elledge, S. J. (2021) · Science · doi:10.1126/science.abg5784 · Cited by 155
Gut microbiota shapes cancer immunotherapy responses
Lei, W., Zhou, K., Lei, Y., Li, Q., & Zhu, H. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00786-8 · Cited by 195
Sorber, L., Zwaenepoel, K., Deschoolmeester, V., Schil, P. E. V., van Meerbeeck, J. P., Lardon, F., Rolfo, C. D., & Pauwels, P. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.04.026 · Cited by 166
Tian, H., Lian, R., Li, Y., Liu, C., Liang, S., Li, W., Tao, T., Wu, X., Ye, Y., Yang, X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18929-0 · Cited by 162
Alessi, J. V., Ricciuti, B., Spurr, L. F., Gupta, H., Li, Y. Y., Glass, C., Nishino, M., Cherniack, A. D., Lindsay, J., Sharma, B., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.03.024 · Cited by 155
An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer
Karasaki, T., Nagayama, K., Kuwano, H., Nitadori, J., Sato, M., Anraku, M., Hosoi, A., Matsushita, H., Morishita, Y., Kashiwabara, K., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.01.005 · Cited by 167
Catalog of 5’ Fusion Partners in ALK-positive NSCLC Circa 2020
Ou, S. I., Zhu, V. W., & Nagasaka, M. (2020) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2020.100015 · Cited by 187
Metabolic Adaptations in Cancer Stem Cells
Yadav, U. P., Singh, T., Kumar, P., Sharma, P., Kaur, H., Sharma, S., Singh, S., Kumar, S., & Mehta, K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01010 · Cited by 161
“Genomic analyses, mRNA profiling and mutational analysis of breast cancer (252), ovarian cancer (253), lung cancer (254), glioblastoma cancer (255), prostate cancer (256), gastric cancer (257), B-cell lymphoma (258), acute lymphoid leukemia (259), metastatic cancers (260), and melanomas (261) has been performed using…”
MethodBinding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed
Yosaatmadja, Y., Silva, S., Dickson, J. M. J. J., Patterson, A. V., Smaill, J. B., Flanagan, J. U., McKeage, M. J., & Squire, C. J. (2015) · Journal of Structural Biology · doi:10.1016/j.jsb.2015.10.018 · Cited by 156
KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance
Zavitsanou, A., Pillai, R., Yuan, H., Wu, W., Bartnicki, E., Karakousi, T. R., Rajalingam, S., Herrera, A. M., Karatza, A., Rashidfarrokhi, A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113295 · Cited by 177
“(E) Growth kinetics of Keap1 wild-type and mutant KP cells in females.”
BackgroundOrtmayr, K., Dubuis, S., & Zampieri, M. (2019) · Nature Communications · doi:10.1038/s41467-019-09695-9 · Cited by 142
Jhaveri, K. L., Wang, X. V., Makker, V., Luoh, S.-W., Mitchell, E. P., Zwiebel, J. A., Sharon, E., Gray, R. J., Li, S., McShane, L. M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz291 · Cited by 151
Yang, L., Yang, J., Zhou, X., Huang, L., Zhao, W., Wang, T., Zhuang, J., & Tian, J. (2018) · European Radiology · doi:10.1007/s00330-018-5770-y · Cited by 161
Jurmeister, P. S., Bockmayr, M. L., Seegerer, P., Bockmayr, T., Treue, D., Montavon, G., Vollbrecht, C., Arnold, A., Teichmann, D., Bressem, K. K., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw8513 · Cited by 174
Schwaederle, M., Husain, H., Fanta, P. T., Piccioni, D. E., Kesari, S., Schwab, R. B., Banks, K. C., Lanman, R. B., Talasaz, A., Parker, B. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7110 · Cited by 149
“Of interest, the frequency of some alterations, such as MET in breast and lung tumors, was higher than previously reported, though the rates reported vary widely by study [24–27].”
Sivakumar, S., Moore, J. A., Montesion, M., Sharaf, R., Lin, D. I., Colón, C. I., Fleischmann, Z., Ebot, E. M., Newberg, J. Y., Mills, J. M., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0620 · Cited by 175
Helicobacter pylori Infection Causes Characteristic DNA Damage Patterns in Human Cells
Koeppel, M., Garcia-Alcalde, F., Glowinski, F., Schlaermann, P., & Meyer, T. F. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.05.030 · Cited by 148
Lung Cancer Subtypes Generate Unique Immune Responses
Busch, S. E., Hanke, M. L., Kargl, J., Metz, H. E., MacPherson, D., & Houghton, A. M. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600576 · Cited by 148
Rogers, Z. N., McFarland, C. D., Winters, I. P., Naranjo, S., Chuang, C.-H., Petrov, D., & Winslow, M. M. (2017) · Nature Methods · doi:10.1038/nmeth.4297 · Cited by 147
Walter, D. M., Venancio, O. S., Buza, E. L., Tobias, J. W., Deshpande, C. G., Gudiel, A. A., Kim-Kiselak, C., Cicchini, M., Yates, T. J., & Feldser, D. M. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2159 · Cited by 161
Su, W., Feng, S., Chen, X., Yang, X., Mao, R., Guo, C., Wang, Z., Thomas, D. G., Lin, J., Reddy, R. M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0222 · Cited by 150
Palakurthi, S., Kuraguchi, M., Zacharek, S. J., Zudaire, E., Huang, W., Bonal, D. M., Liu, J., Dhaneshwar, A., DePeaux, K., Gowaski, M. R., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0595 · Cited by 147
Brohl, A. S., Kahen, E., Yoder, S., Teer, J. K., & Reed, D. R. (2017) · Scientific Reports · doi:10.1038/s41598-017-15183-1 · Cited by 152
Non-coding RNAs as liquid biopsy biomarkers in cancer
Toden, S., & Goel, A. (2022) · British Journal of Cancer · doi:10.1038/s41416-021-01672-8 · Cited by 167
Schwaederlé, M. C., Patel, S. P., Husain, H., Ikeda, M., Lanman, R. B., Banks, K. C., Talasaz, A., Bazhenova, L., & Kurzrock, R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2497 · Cited by 145
Almodovar, K., Iams, W. T., Meador, C. B., Zhao, Z., York, S. J., Horn, L., Yan, Y., Hernandez, J., Chen, H., Shyr, Y., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.09.1951 · Cited by 150
The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer
Kim, J., Lee, H. M., Cai, F., Ko, B., Yang, C., Lieu, E. L., Muhammad, N., Rhyne, S., Li, K., Haloul, M., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00316-0 · Cited by 142
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer
Tong, X., Patel, A. S., Kim, E., Li, H., Chen, Y., Li, S., Liu, S., Dilly, J., Kapner, K. S., Zhang, N., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.01.012 · Cited by 142
Self-citationMultiplatform-based molecular subtypes of non-small-cell lung cancer
Chen, F., Zhang, Y., Parra, E. R., Rodriguez‐Canales, J., Behrens, C., Akbani, R., Lu, Y., Kurie, J. M., Gibbons, D. L., Mills, G. B., et al. (2016) · Oncogene · doi:10.1038/onc.2016.303 · Cited by 160
Smith, J. C., & Sheltzer, J. M. (2018) · eLife · doi:10.7554/elife.39217 · Cited by 141
Intracellular and extracellular TGF-β signaling in cancer: some recent topics
Miyazono, K., Katsuno, Y., Koinuma, D., Ehata, S., & Morikawa, M. (2018) · Frontiers of Medicine · doi:10.1007/s11684-018-0646-8 · Cited by 140
Molecular targeted therapy in the treatment of advanced stage non‐small cell lung cancer ( NSCLC )
Kumarakulasinghe, N. B., van Zanwijk, N., & Soo, R. A. (2015) · Respirology · doi:10.1111/resp.12490 · Cited by 155
Large-scale screening for somatic mutations in lung cancer
Rosell, R., & Karachaliou, N. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01125-3 · Cited by 149
The National Lung Matrix Trial of personalized therapy in lung cancer
Middleton, G., Fletcher, P., Popat, S., Savage, J., Summers, Y., Greystoke, A., Gilligan, D., Cave, J., O’Rourke, N., Brewster, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2481-8 · Cited by 140
Lamberti, G., Andrini, E., Sisi, M., Rizzo, A., Parisi, C., Federico, A. D., Gelsomino, F., & Ardizzoni, A. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103119 · Cited by 154
Nongenetic Evolution Drives Lung Adenocarcinoma Spatial Heterogeneity and Progression
Tavernari, D., Battistello, E., Dheilly, E., Petruzzella, A. S., Mina, M., Sordet‐Dessimoz, J., Peters, S., Krueger, T., Gfeller, D., Riggi, N., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1274 · Cited by 152
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Venue
- Nature
- Published
- 2014-07-09
- Volume
- 511
- Issue
- 7511
- Pages
- 543-550
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4231481
- OpenAlex
- W2180481128
- Cited by
- 5,732
- References
- 42
- Citations by year
- 2026: 314 · 2025: 415 · 2024: 428 · 2023: 523 · 2022: 547 · 2021: 614 · 2020: 613 · 2019: 495 · 2018: 478 · 2017: 516 · 2016: 427 · 2015: 312 · 2014: 47
- FWCI
- 347.50
- Type
- journal article
- Language
- en
- Update notices
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nc-sa)
- SERVAL (Université de Lausanne) (acceptedVersion, cc-by-nc-sa)
- eScholarship (California Digital Library) (submittedVersion)
- IRIS (submittedVersion, cc-by-nc-sa)
- eSpace (Curtin University) (submittedVersion)
- Scholarworks@UNIST (Ulsan National Institute of Science and Technology) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health (UL1TR000005)
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG003273, R01HG006272)
- National Cancer Institute (U24CA126554, U24CA143882, U24CA143843, U24CA143840, U24CA126546, CA143883, U24CA143858, K08CA137153, U24CA126543, U24CA144025, U24CA126563, U24CA143866, U24CA143883, CA143840, U24 CA137153, U24CA143845, U24CA126544, U24CA180951, U24CA143867, U24CA143848, U24CA143799, U24CA126551, U24CA143835, U24CA126561, P30CA177558, P30CA008748, P30CA016672, P30CA006973)
- National Institute of General Medical Sciences (T32GM007753)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- lung adenocarcinoma, somatic mutations, RIT1, MGA, MYC amplification, EGFR mutation, RBM10, neurofibromatosis type 1, MET, ERBB2, MET exon 14 skipping, splicing alterations, MAPK signaling, PI3K signaling, DNA methylation, microRNA, transcriptome, proteome, molecular classification, carcinogenesis
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Female, Humans, Lung Neoplasms, Male, Mutation, Oncogenes, Sex Factors, Gene Expression Regulation, Neoplastic, Gene Dosage, Cell Cycle Proteins, Genomics, Molecular Typing, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.